AI주식인사이트AI Stock Insight
C

풍전약품

298060KOSDAQ의약품 제조업

48.5 / 100

Reference Date: 2026-07-24

Financial Score16.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly up 1.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

SCM Life Science is a biotech company that develops high-purity stem cell therapeutics using its proprietary layer separation culture technology. It is conducting clinical trials for treatments targeting chronic graft-versus-host disease, acute pancreatitis, and atopic dermatitis. Additionally, it has launched the dermocosmetic brand 'Iroro,' leveraging CXCL1 protein and hPL cultivation technology, and is expanding globally through international sales agreements.

Number of Employees

25people

Average Salary

37.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
442.50Industry Average 11.230.0Point

39.4x industry avg (risky)

PBR
0.71Industry Average 0.814.0Point

In line with industry avg

ROE
0.81Industry Average 4.011.0Point

Well below industry avg

Debt Ratio
7.36Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲1404.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲36.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -59.1% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 0Neutral 3Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position6.0Point

52w upper range (64%)

Current 2,655Won52-week high 3,70552-week low 764
1-month return3.0Point

1m 1.72% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-06
  • Neutral주식등의대량보유상황보고서(일반)2026-07-06
  • Neutral증권발행결과(자율공시) (제3자배정)2026-06-30